A multicentre, triple blind, placebo controlled, parallel group study of atorvastatin in chronic migraine

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502177-42-02

Acronym

2022-502177-42-02

Enrollment

300

Registered

2023-06-23

Start date

2024-05-13

Completion date

Unknown

Last updated

2024-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic migraine

Brief summary

Difference between groups receiving atorvastatin 40 mg daily and placebo in change from baseline in number of migraine days per 4 weeks

Detailed description

Difference between groups receiving atorvastatin 40 mg daily and placebo in change from baseline in number of days with headache, Number of reported side effects in the placebo and atorvastatin 40 mg, Comparison of cost in the placebo and atorvastatin treatment, taking into consideration price of the medicine, price of acute medication, and lost worktime

Interventions

DRUGATORVASTATIN

DRUGPLACEBO

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Difference between groups receiving atorvastatin 40 mg daily and placebo in change from baseline in number of migraine days per 4 weeks	—

Secondary

Measure	Time frame
Difference between groups receiving atorvastatin 40 mg daily and placebo in change from baseline in number of days with headache, Number of reported side effects in the placebo and atorvastatin 40 mg, Comparison of cost in the placebo and atorvastatin treatment, taking into consideration price of the medicine, price of acute medication, and lost worktime	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026